MX2007006373A - Regimen de dosificacion de un agonista del receptor s1p. - Google Patents

Regimen de dosificacion de un agonista del receptor s1p.

Info

Publication number
MX2007006373A
MX2007006373A MX2007006373A MX2007006373A MX2007006373A MX 2007006373 A MX2007006373 A MX 2007006373A MX 2007006373 A MX2007006373 A MX 2007006373A MX 2007006373 A MX2007006373 A MX 2007006373A MX 2007006373 A MX2007006373 A MX 2007006373A
Authority
MX
Mexico
Prior art keywords
daily dosage
dosage regimen
receptor agonist
dosage
standard
Prior art date
Application number
MX2007006373A
Other languages
English (en)
Inventor
John M Kovarik
Silke Appel-Dingemanse
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36046868&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007006373(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2007006373A publication Critical patent/MX2007006373A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Storage Device Security (AREA)

Abstract

Se administran moduladores o agonistas de receptor S1P siguiente a un regimen de dosificacion por el que durante los 3 a 6 dias iniciales de tratamiento la dosificacion diaria se eleva de manera que se administra en total R veces (siendo R el factor de acumulacion) la dosificacion diaria estandar y despues se continua en la dosificacion diaria estandar o a una dosificacion diaria menor que la dosificacion diaria estandar.
MX2007006373A 2004-11-29 2005-11-28 Regimen de dosificacion de un agonista del receptor s1p. MX2007006373A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63148304P 2004-11-29 2004-11-29
PCT/US2005/043044 WO2006058316A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist

Publications (1)

Publication Number Publication Date
MX2007006373A true MX2007006373A (es) 2007-06-20

Family

ID=36046868

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006373A MX2007006373A (es) 2004-11-29 2005-11-28 Regimen de dosificacion de un agonista del receptor s1p.

Country Status (22)

Country Link
US (3) US20090275553A1 (es)
EP (3) EP2359821A1 (es)
JP (4) JP2008521827A (es)
KR (4) KR20130041385A (es)
CN (2) CN102600472A (es)
AU (1) AU2005309378B2 (es)
BR (1) BRPI0518674A2 (es)
CA (1) CA2589265A1 (es)
ES (1) ES2495690T3 (es)
HK (1) HK1109057A1 (es)
IL (2) IL183134A0 (es)
MA (1) MA29034B1 (es)
MX (1) MX2007006373A (es)
NO (2) NO20072401L (es)
NZ (2) NZ554720A (es)
PL (1) PL1819326T3 (es)
PT (1) PT1819326E (es)
RU (2) RU2478384C2 (es)
SG (2) SG187468A1 (es)
TN (1) TNSN07209A1 (es)
WO (1) WO2006058316A1 (es)
ZA (1) ZA200703328B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070058455A (ko) 2004-08-13 2007-06-08 프래시스 파마슈티컬즈 인코포레이티드 스핑고신-1-포스페이트(ｓ1ｐ) 수용체 활성을 조절하기위한 방법 및 조성물
RU2478384C2 (ru) * 2004-11-29 2013-04-10 Новартис Аг Курс лечения с использованием агониста рецептора s1p
RU2493840C2 (ru) * 2005-09-09 2013-09-27 Новартис Аг Лечение аутоиммунных заболеваний
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
MX2009011943A (es) 2007-05-04 2009-11-13 Novartis Ag Uso de modulador de los receptores de la sip.
ES2617628T5 (es) 2008-03-17 2020-06-01 Actelion Pharmaceuticals Ltd Régimen de dosificación para un agonista selectivo del receptor de S1P1
JPWO2009142195A1 (ja) * 2008-05-20 2011-09-29 杏林製薬株式会社 寛解導入維持剤
CN102105144B (zh) * 2008-07-23 2013-11-13 诺华股份有限公司 鞘氨醇1磷酸酯受体调节剂以及它们用于制备治疗肌肉炎症的药物的用途
CN103271905A (zh) * 2008-08-18 2013-09-04 诺瓦提斯公司 用于治疗周围神经病的化合物
CN102256942B (zh) * 2008-12-18 2013-07-24 诺瓦提斯公司 1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的多晶型物
US8486930B2 (en) * 2008-12-18 2013-07-16 Novartis Ag Salts
IL294514A (en) * 2008-12-18 2022-09-01 Novartis Ag 1-[4-[1[(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid mipomarate salt
AR074825A1 (es) * 2008-12-22 2011-02-16 Novartis Ag Regimen de dosificacion de un agonista de los receptores de s1p, metodo de tratamiento y kit
AU2015275246B2 (en) * 2008-12-22 2018-02-01 Novartis Ag Dosage regimen for a S1P receptor agonist
LT3409274T (lt) * 2008-12-22 2020-02-10 Novartis Ag Dozavimo schema s1p receptoriaus agonistui
EP3061449A1 (en) * 2009-09-29 2016-08-31 Novartis AG Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
WO2011138398A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives
US20150218090A1 (en) * 2011-10-21 2015-08-06 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
JP6322630B2 (ja) 2012-08-17 2018-05-09 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ （２Ｚ，５Ｚ）−５−（３−クロロ−４−（（Ｒ）−２，３−ジヒドロキシプロポキシ）ベンジリデン）−２−（プロピルイミノ）−３−（ｏ−トリル）チアゾリジン−４−オンの製造方法及び前記方法において使用される中間体
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
KR101820330B1 (ko) 2013-10-11 2018-01-19 테이코쿠 팔마 유에스에이, 인코포레이티드 국소 스핑고신-1-포스페이트 수용체 효현제 제형 및 이의 사용 방법
MY188764A (en) 2014-12-11 2021-12-30 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US10250466B2 (en) * 2016-03-29 2019-04-02 Juniper Networks, Inc. Application signature generation and distribution
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2579602B2 (ja) 1992-10-21 1997-02-05 吉富製薬株式会社 ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
ATE211726T1 (de) 1994-08-22 2002-01-15 Welfide Corp Benzolderivate und deren medizinische verwendung
RU2156127C2 (ru) * 1995-12-28 2000-09-20 Еситоми Фармасьютикал Индустриз, Лтд. Препарат местного применения для иммуносупрессии и лечения аутоиммунных или аллергических заболеваний
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
CA2282378C (en) * 1997-02-27 2008-12-30 Yoshitomi Pharmaceutical Industries Ltd. Pharmaceutical composition
IL155066A (en) 1997-04-04 2004-06-20 Mitsubishi Pharma Corp History 2 - Amino - 2 - (2 - Ethyl (converted)) Propane - 1, 3 - Diol Efficacy in the preparation of 2 - Aminopropene - 1, 3 - Diol
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11116479A (ja) * 1997-10-10 1999-04-27 Sugen Inc 脳癌のための組み合わせ化学療法処置
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
JP2004507552A (ja) 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体
ATE314383T1 (de) 2001-03-26 2006-01-15 Novartis Pharma Gmbh 2-amino-propanol derivate
US20020197256A1 (en) * 2001-04-02 2002-12-26 Genentech, Inc. Combination therapy
NZ528284A (en) * 2001-04-02 2005-04-29 Astrazeneca Ab Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and PVP
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
AU2002320828B2 (en) * 2001-06-08 2006-02-02 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
WO2003029184A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
US6960692B2 (en) 2001-09-27 2005-11-01 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
AU2003216054B2 (en) 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
CA2472715A1 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
KR20050054958A (ko) * 2002-09-24 2005-06-10 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트수용체 아고니스트
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CL2004001120A1 (es) 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
RU2478384C2 (ru) * 2004-11-29 2013-04-10 Новартис Аг Курс лечения с использованием агониста рецептора s1p
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas

Also Published As

Publication number Publication date
NO20072401L (no) 2007-06-22
JP2015061883A (ja) 2015-04-02
CN101068536A (zh) 2007-11-07
HK1109057A1 (en) 2008-05-30
EP1819326B1 (en) 2014-07-02
CN101068536B (zh) 2012-12-05
KR20140095109A (ko) 2014-07-31
ZA200703328B (en) 2008-08-27
US20120071446A1 (en) 2012-03-22
MA29034B1 (fr) 2007-11-01
RU2012141951A (ru) 2014-04-10
RU2478384C2 (ru) 2013-04-10
AU2005309378A1 (en) 2006-06-01
IL223502A0 (en) 2013-02-03
KR20150028858A (ko) 2015-03-16
RU2007124327A (ru) 2009-01-10
US20090275553A1 (en) 2009-11-05
EP2384749A1 (en) 2011-11-09
CN102600472A (zh) 2012-07-25
US20150087720A1 (en) 2015-03-26
JP2008521827A (ja) 2008-06-26
CA2589265A1 (en) 2006-06-01
PT1819326E (pt) 2014-09-25
AU2005309378B2 (en) 2010-02-11
NO20121305L (no) 2007-06-22
PL1819326T3 (pl) 2014-12-31
NZ590054A (en) 2012-07-27
SG187468A1 (en) 2013-02-28
KR20130041385A (ko) 2013-04-24
JP2013129664A (ja) 2013-07-04
NZ554720A (en) 2011-04-29
TNSN07209A1 (en) 2008-11-21
EP1819326A1 (en) 2007-08-22
KR20070085465A (ko) 2007-08-27
BRPI0518674A2 (pt) 2008-12-02
WO2006058316A1 (en) 2006-06-01
EP2359821A1 (en) 2011-08-24
IL183134A0 (en) 2008-04-13
ES2495690T3 (es) 2014-09-17
SG158096A1 (en) 2010-01-29
JP2012107059A (ja) 2012-06-07

Similar Documents

Publication Publication Date Title
TNSN07209A1 (en) Dosage regimen of an s1p receptor agonist
MX367667B (es) Régimen de dosificación de un agonista de los receptores de s1p.
MXPA02007690A (es) Composiciones de liberacion controlada que contienen agonista y antiagonista de opioide.
MA32397B1 (fr) Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
EP2335734A3 (en) Treatment of pain and other alpha 2 adrenergic-mediated conditions
MX2007000009A (es) Forma farmaceutica oral, protegida frente al abuso.
HRP20050077B1 (hr) Postupci i oblici doziranja za kontrolirano oslobađanje paliperidona
ATE383876T1 (de) Analgistische darreichungsform, die nicht parenteral oder inhalation dosiert werden können
EP2044940A3 (en) Methods of treating patients suffering from movement disorders
PT1414451E (pt) Formulações agonistas de opióides com antagonista libertável e sequestrado
WO2006000567A3 (en) Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function
IL178591A (en) 4– (Amino) –2– (2,6 – Dioxo (3-piperidyl)) - Isoindulin – 1,3 – Dion for the treatment and management of myelodysplastic syndromes
ZA200810124B (en) Pharmaceutical combination comprising 3-(3-dimethyl-amino-1-ethyl-2-methyl-propyl)-phenol and Paracetamol
MX2008007897A (es) Metodos para administrar transdermicamente un agonista de receptor de indol serotonina y composiciones transdermicas para uso con los mismos.
TW200738269A (en) Oral delivery of therapeutic agents using tight junction agonists
MX2009013779A (es) Uso de agonistas de tlr y/o interferonas tipo 1 para aliviar la toxicidad de los regimenes terapeuticos de agonistas de tnf-r.
MA26964A1 (fr) Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase.
HK1127556A1 (en) Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
MX2010008220A (es) Metodos que usan compuestos inmunomoduladores para modular nivel de cd59.
GEP201606538B (en) Preoperative treatment of post operative pain
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
EP1051995A3 (en) 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
IL151058A0 (en) Controlled-release compositions containing opioid agonist and antagonist
SE9904424D0 (sv) Use of interleukin-6 in combination with leptin in treatment of obesity
NO20064123L (no) Farmasoytisk blanding av [+]-erytro-meflokin og dens anvendelse

Legal Events

Date Code Title Description
FG Grant or registration